Is there a silver lining to the Ebola epidemic in West Africa which has claimed nearly 10,000 lives over the past year?
Yes, says A. Townsend Peterson, of the University of Kansas, in the journal PLoS Neglected Tropical Diseases. Finally, he argues, Ebola will get the funding needed to develop effective vaccines and treatments.
Ebola is only one of a number of diseases which cripple developing countries, but which are ignored in the developed world because no one there is in danger. But as soon as governments realised that Ebola could easily spread from West Africa to anywhere in the world, the funding tap was opened.
One example of this dynamic is the West Nile virus, which has become endemic in the US. Between 1942 and 1998, 278 articles dealt with it in scholarly journals. After it arrived in 1999, the number of publications has averaged 420 a year. Scientific interest in Ebola is following a similar pattern.
If the present situation with Ebola is to offer any lessons, they are that the only hope for serious investment in reducing the incidence and impact of such diseases is via spread to developed countries. Once such spread occurs, research and pharmaceutical investment will most likely follow. Ebola is a positive example, and clearly Ebola research will enter a new phase of progress, innovation, funding, production of key pharmaceuticals, and improved care, hopefully for all who might be infected by this virus.
In effect, what Ebola did was to cross the line between being a “neglected tropical disease” and being an “emerging infection.”
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.